Clinical Evaluation of Imipenem/Cilastatin Sodium and Fosfomycin as Second-Line Combination Chemotherapy in Severe Infections Associated with Hematologic Disorders

Shoichiro Tsuda; Yuko Kuzuyama; Hiroyuki Nakai; Taku Seriu; Teruyuki Takashima; Sinji Tanaka; Shigeo Horiike; Masafumi Taniwaki; Shinichi Misawa; Kei Kashima; Hitoshi Nakagawa; Hiroshi Fujii; Tetsuro Nakai; Yasuo Okawara; Hitosi Imanishi; Shohei Yokota; Hikari Nishigaki; Kazuhiro Nishida

doi:10.11553/antibiotics1968b.46.171

Clinical Evaluation of Imipenem/Cilastatin Sodium and Fosfomycin as Second-Line Combination Chemotherapy in Severe Infections Associated with Hematologic Disorders

Shoichiro Tsuda, Yuko Kuzuyama, Hiroyuki Nakai, Taku Seriu, Teruyuki Takashima, Sinji Tanaka, Shigeo Horiike, Masafumi Taniwaki, Shinichi Misawa, Kei Kashima, Hitoshi Nakagawa, Hiroshi Fujii, Tetsuro Nakai, Yasuo Okawara, Hitosi Imanishi, Shohei Yokota, Hikari Nishigaki, Kazuhiro Nishida

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Imipenem/cilastatin sodium (IPM/CS) which is a broad-spectrum agent against both Gram-positive and -negative bacteria was used in combination with fosfomycin (FOM) as a second-line chemotherapy for severe infections associated with hematologic disorders. FOM was partnered with IPM because FOM may enhance the bacteriocidal effects of IPM when given as pretreatment to IPM/CS therapy.

Original language	English (US)
Pages (from-to)	171-183
Number of pages	13
Journal	Japanese Journal of Antibiotics
Volume	46
Issue number	2
DOIs	https://doi.org/10.11553/antibiotics1968b.46.171
State	Published - 1993
Externally published	Yes

ASJC Scopus subject areas

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

Access to Document

10.11553/antibiotics1968b.46.171

Cite this

Tsuda, S., Kuzuyama, Y., Nakai, H., Seriu, T., Takashima, T., Tanaka, S., Horiike, S., Taniwaki, M., Misawa, S., Kashima, K., Nakagawa, H., Fujii, H., Nakai, T., Okawara, Y., Imanishi, H., Yokota, S., Nishigaki, H., & Nishida, K. (1993). Clinical Evaluation of Imipenem/Cilastatin Sodium and Fosfomycin as Second-Line Combination Chemotherapy in Severe Infections Associated with Hematologic Disorders. Japanese Journal of Antibiotics, 46(2), 171-183. https://doi.org/10.11553/antibiotics1968b.46.171

Tsuda, S, Kuzuyama, Y, Nakai, H, Seriu, T, Takashima, T, Tanaka, S, Horiike, S, Taniwaki, M, Misawa, S, Kashima, K, Nakagawa, H, Fujii, H, Nakai, T, Okawara, Y, Imanishi, H, Yokota, S, Nishigaki, H & Nishida, K 1993, 'Clinical Evaluation of Imipenem/Cilastatin Sodium and Fosfomycin as Second-Line Combination Chemotherapy in Severe Infections Associated with Hematologic Disorders', Japanese Journal of Antibiotics, vol. 46, no. 2, pp. 171-183. https://doi.org/10.11553/antibiotics1968b.46.171

@article{9f342c748a244e4a95b037ca2ea73bc6,

title = "Clinical Evaluation of Imipenem/Cilastatin Sodium and Fosfomycin as Second-Line Combination Chemotherapy in Severe Infections Associated with Hematologic Disorders",

abstract = "Imipenem/cilastatin sodium (IPM/CS) which is a broad-spectrum agent against both Gram-positive and -negative bacteria was used in combination with fosfomycin (FOM) as a second-line chemotherapy for severe infections associated with hematologic disorders. FOM was partnered with IPM because FOM may enhance the bacteriocidal effects of IPM when given as pretreatment to IPM/CS therapy.",

author = "Shoichiro Tsuda and Yuko Kuzuyama and Hiroyuki Nakai and Taku Seriu and Teruyuki Takashima and Sinji Tanaka and Shigeo Horiike and Masafumi Taniwaki and Shinichi Misawa and Kei Kashima and Hitoshi Nakagawa and Hiroshi Fujii and Tetsuro Nakai and Yasuo Okawara and Hitosi Imanishi and Shohei Yokota and Hikari Nishigaki and Kazuhiro Nishida",

year = "1993",

doi = "10.11553/antibiotics1968b.46.171",

language = "English (US)",

volume = "46",

pages = "171--183",

journal = "Japanese Journal of Antibiotics",

issn = "0368-2781",

publisher = "Japan Antibiotics Research Association",

number = "2",

}

TY - JOUR

T1 - Clinical Evaluation of Imipenem/Cilastatin Sodium and Fosfomycin as Second-Line Combination Chemotherapy in Severe Infections Associated with Hematologic Disorders

AU - Tsuda, Shoichiro

AU - Kuzuyama, Yuko

AU - Nakai, Hiroyuki

AU - Seriu, Taku

AU - Takashima, Teruyuki

AU - Tanaka, Sinji

AU - Horiike, Shigeo

AU - Taniwaki, Masafumi

AU - Misawa, Shinichi

AU - Kashima, Kei

AU - Nakagawa, Hitoshi

AU - Fujii, Hiroshi

AU - Nakai, Tetsuro

AU - Okawara, Yasuo

AU - Imanishi, Hitosi

AU - Yokota, Shohei

AU - Nishigaki, Hikari

AU - Nishida, Kazuhiro

PY - 1993

Y1 - 1993

N2 - Imipenem/cilastatin sodium (IPM/CS) which is a broad-spectrum agent against both Gram-positive and -negative bacteria was used in combination with fosfomycin (FOM) as a second-line chemotherapy for severe infections associated with hematologic disorders. FOM was partnered with IPM because FOM may enhance the bacteriocidal effects of IPM when given as pretreatment to IPM/CS therapy.

AB - Imipenem/cilastatin sodium (IPM/CS) which is a broad-spectrum agent against both Gram-positive and -negative bacteria was used in combination with fosfomycin (FOM) as a second-line chemotherapy for severe infections associated with hematologic disorders. FOM was partnered with IPM because FOM may enhance the bacteriocidal effects of IPM when given as pretreatment to IPM/CS therapy.

UR - http://www.scopus.com/inward/record.url?scp=0027414510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027414510&partnerID=8YFLogxK

U2 - 10.11553/antibiotics1968b.46.171

DO - 10.11553/antibiotics1968b.46.171

M3 - Article

C2 - 8331778

AN - SCOPUS:0027414510

SN - 0368-2781

VL - 46

SP - 171

EP - 183

JO - Japanese Journal of Antibiotics

JF - Japanese Journal of Antibiotics

IS - 2

ER -

Clinical Evaluation of Imipenem/Cilastatin Sodium and Fosfomycin as Second-Line Combination Chemotherapy in Severe Infections Associated with Hematologic Disorders

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this